Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Enroll crawled time : 14:01 save search
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
PHAT | $9.12 0.66% 0.66% 440K
|
Health Technology
|
| O: 1.6%
H: 1.49%
C: 1.02%
phase 3 trial enroll
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Published: 2020-12-22 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.38%
H: 0.75%
C: -3.01%
urea trial enroll
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 3.14%
H: 1.5%
C: -2.26%
phase 3 treatment enroll
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.